MA45988B1 - Triple combinaison d'agonistes inverses du récepteur d'histamine-3, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteurs nmda - Google Patents
Triple combinaison d'agonistes inverses du récepteur d'histamine-3, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteurs nmdaInfo
- Publication number
- MA45988B1 MA45988B1 MA45988A MA45988A MA45988B1 MA 45988 B1 MA45988 B1 MA 45988B1 MA 45988 A MA45988 A MA 45988A MA 45988 A MA45988 A MA 45988A MA 45988 B1 MA45988 B1 MA 45988B1
- Authority
- MA
- Morocco
- Prior art keywords
- histamine
- receptor
- inverse agonists
- acetylcholinesterase inhibitors
- triple combination
- Prior art date
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 3
- 239000002469 receptor inverse agonist Substances 0.000 title abstract 2
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 229940009098 aspartate Drugs 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 229940125425 inverse agonist Drugs 0.000 abstract 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne une combinaison d'un agoniste inverse du récepteur de l'histamine-3, d'un inhibiteur de l'acétylcholinestérase et d'un antagoniste du récepteur nmda. L'invention concerne également un agoniste inverse du récepteur de l'histamine-3 (h3r) ou les 10 sels pharmaceutiquement acceptables de celui-ci, en combinaison avec un inhibiteur de l'acétylcholinestérase et un antagoniste du récepteur de n-méthyl-d-aspartate (nmda) ou comme adjuvant à ceux-ci, ainsi que leur utilisation dans le traitement des troubles cognitifs. L'invention concerne encore une composition pharmaceutique contenant ladite combinaison.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641028165 | 2016-08-18 | ||
| PCT/IB2017/054939 WO2018033848A1 (fr) | 2016-08-18 | 2017-08-14 | Triple combinaison d'agonistes inverses du récepteur d'histamine-3, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteurs nmda |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45988A MA45988A (fr) | 2019-06-26 |
| MA45988B1 true MA45988B1 (fr) | 2020-10-28 |
Family
ID=59829422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45988A MA45988B1 (fr) | 2016-08-18 | 2017-08-14 | Triple combinaison d'agonistes inverses du récepteur d'histamine-3, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteurs nmda |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20190336509A1 (fr) |
| EP (1) | EP3500306B1 (fr) |
| JP (1) | JP6734469B2 (fr) |
| KR (1) | KR102040639B1 (fr) |
| CN (1) | CN109562180B (fr) |
| AU (1) | AU2017311666B2 (fr) |
| BR (1) | BR112019002637A2 (fr) |
| CA (1) | CA3033050C (fr) |
| CY (1) | CY1123522T1 (fr) |
| DK (1) | DK3500306T3 (fr) |
| EA (1) | EA036480B1 (fr) |
| ES (1) | ES2818898T3 (fr) |
| HR (1) | HRP20201511T1 (fr) |
| HU (1) | HUE051474T2 (fr) |
| IL (1) | IL264405B (fr) |
| LT (1) | LT3500306T (fr) |
| MA (1) | MA45988B1 (fr) |
| MD (1) | MD3500306T2 (fr) |
| MX (1) | MX2019001698A (fr) |
| PL (1) | PL3500306T3 (fr) |
| PT (1) | PT3500306T (fr) |
| RS (1) | RS60832B1 (fr) |
| SG (1) | SG11201900680PA (fr) |
| SI (1) | SI3500306T1 (fr) |
| WO (1) | WO2018033848A1 (fr) |
| ZA (1) | ZA201900436B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019229509A1 (fr) | 2018-05-31 | 2019-12-05 | Suven Life Sciences Limited | Méthode de traitement avec un agoniste inverse du récepteur de l'histamine-3 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103443093B (zh) * | 2011-02-23 | 2015-02-25 | 苏文生命科学有限公司 | 作为组胺h3受体配体的化合物 |
| FR2974729B1 (fr) * | 2011-05-02 | 2013-04-19 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
-
2017
- 2017-08-14 JP JP2019506623A patent/JP6734469B2/ja not_active Expired - Fee Related
- 2017-08-14 WO PCT/IB2017/054939 patent/WO2018033848A1/fr unknown
- 2017-08-14 AU AU2017311666A patent/AU2017311666B2/en not_active Ceased
- 2017-08-14 SG SG11201900680PA patent/SG11201900680PA/en unknown
- 2017-08-14 ES ES17764658T patent/ES2818898T3/es active Active
- 2017-08-14 CN CN201780048908.1A patent/CN109562180B/zh active Active
- 2017-08-14 MA MA45988A patent/MA45988B1/fr unknown
- 2017-08-14 DK DK17764658.5T patent/DK3500306T3/da active
- 2017-08-14 CA CA3033050A patent/CA3033050C/fr active Active
- 2017-08-14 BR BR112019002637A patent/BR112019002637A2/pt active Search and Examination
- 2017-08-14 EP EP17764658.5A patent/EP3500306B1/fr active Active
- 2017-08-14 MD MDE20190713T patent/MD3500306T2/ro unknown
- 2017-08-14 HU HUE17764658A patent/HUE051474T2/hu unknown
- 2017-08-14 PT PT177646585T patent/PT3500306T/pt unknown
- 2017-08-14 PL PL17764658T patent/PL3500306T3/pl unknown
- 2017-08-14 MX MX2019001698A patent/MX2019001698A/es active IP Right Grant
- 2017-08-14 RS RS20201135A patent/RS60832B1/sr unknown
- 2017-08-14 SI SI201730420T patent/SI3500306T1/sl unknown
- 2017-08-14 US US16/319,668 patent/US20190336509A1/en not_active Abandoned
- 2017-08-14 EA EA201990481A patent/EA036480B1/ru unknown
- 2017-08-14 KR KR1020197007052A patent/KR102040639B1/ko active IP Right Grant
- 2017-08-14 LT LTEP17764658.5T patent/LT3500306T/lt unknown
-
2019
- 2019-01-22 IL IL264405A patent/IL264405B/en active IP Right Grant
- 2019-01-22 ZA ZA2019/00436A patent/ZA201900436B/en unknown
-
2020
- 2020-09-21 HR HRP20201511TT patent/HRP20201511T1/hr unknown
- 2020-09-22 CY CY20201100891T patent/CY1123522T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31396B1 (fr) | Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes | |
| MA42292A (fr) | Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b | |
| MA39898B1 (fr) | Composés 4-amino-imidazoquinoline | |
| MA31867B1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
| BRPI0612072A2 (pt) | inibidores da aspartil protease | |
| MA37888A1 (fr) | Composition pharmaceutique enrobée contenant du régorafenib | |
| MA38949A1 (fr) | Forme saline d'hydrochlorure pour inhibition d'ezh2 | |
| BRPI0519792A2 (pt) | antagonistas do receptor 5-ht7 | |
| MA33984B1 (fr) | Stimulateurs de sgc ou activateurs de sgc seuls ou en combinaison avec des inhibiteurs de pde5 pour le traitement de la fibrose kystique | |
| MA35107B1 (fr) | Composition pharmaceutique antihypertensive | |
| MA41634B1 (fr) | Formulation à base de combinaison de tésofensine et de métoprolol | |
| CO2021003391A2 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| MA55821B1 (fr) | Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA45002B1 (fr) | Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda | |
| MA45639B1 (fr) | Combinaison d'antagonistes purs du récepteur 5-ht6 avec des inhibiteurs d'acétylcholinestérase | |
| PH12021550549A1 (en) | Dp antagonist | |
| MA45988B1 (fr) | Triple combinaison d'agonistes inverses du récepteur d'histamine-3, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteurs nmda | |
| MA45990B1 (fr) | Combinaison d'agonistes inverses du récepteur de l'histamine-3 avec des inhibiteurs de l'acétylcholinestérase | |
| PH12019500327A1 (en) | Indazole compounds for use in tendon and/or ligament injuries | |
| BR112022008367A2 (pt) | Antagonistas heterocíclicos de nmda | |
| MA44383B1 (fr) | Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer | |
| MA46625B1 (fr) | Inhibiteurs de lsd1 et leurs utilisations médicales | |
| MA40657A1 (fr) | Composition pharmaceutique stable comprenant du pemetrexed ou un sel pharmaceutiquement acceptable de celui-ci |